Valuation: NovoCure Limited

Market Cap 1.38B 1.25B 1.16B 1.05B 1.97B 130B 2.04B 13.93B 5.52B 69.66B 5.19B 5.08B 221B P/E 2026 *
-11.2x
P/E 2027 * -16.3x
Enterprise Value 1.28B 1.16B 1.07B 966M 1.82B 120B 1.89B 12.86B 5.1B 64.35B 4.79B 4.69B 204B EV / Sales 2026 *
1.73x
EV / Sales 2027 * 1.45x
Free-Float
90.08%
Yield 2026 *
-
Yield 2027 * -
1 day+0.94%
1 week-10.92%
Current month-10.04%
1 month-14.52%
3 months-30.21%
6 months-34.46%
Current year-8.51%
1 week 11.44
Extreme 11.435
13.22
1 month 11.44
Extreme 11.435
16.09
Current year 9.82
Extreme 9.82
21.45
1 year 9.82
Extreme 9.82
21.45
3 years 9.82
Extreme 9.82
34.13
5 years 9.82
Extreme 9.82
120.03
10 years 6
Extreme 6
232.76
Manager TitleAgeSince
Chief Executive Officer 46 01/12/2025
Director of Finance/CFO 52 01/01/2025
Chief Tech/Sci/R&D Officer - 17/01/2023
Director TitleAgeSince
Director/Board Member 59 01/01/2012
Chairman 63 01/01/2009
Director/Board Member 64 05/08/2011
Date Insider Type Main position Quantity % Market Cap. Importance
2/11/26 Sell

Head of Human Resources

-660 0.0006%
30/6/26 Free

Chief Executive Officer

1,905 0.0016%
30/6/26 Free

Head of Human Resources

1,905 0.0016%
Change 5-day change 1-year change 3-year change Capi.($)
+0.94%-10.92%+4.51%-7.58% 1.38B
+1.18%-1.28%-16.90%+11.78% 188B
+1.85%+1.04%+7.29%+41.70% 126B
-0.88%-4.98%-14.52%+9.40% 118B
+1.36%-5.91%-42.82%+1.32% 92.48B
+2.96%+7.64%-0.80%+84.71% 68.51B
+1.08%+2.90%+12.95%-6.56% 59.39B
+0.89%+4.17%+2.07%+55.03% 55.48B
-0.68%+6.83%-1.08%+55.36% 49.62B
+1.79%+0.10%-0.55%-8.36% 35.17B
Average +1.05%-0.52%-4.99%+23.68% 79B
Weighted average by Cap. +1.04%-0.40%-9.03%+24.70%

Financials

2026 *2027 *
Net sales 740M 671M 620M 560M 1.05B 69.79B 1.09B 7.45B 2.96B 37.28B 2.78B 2.72B 118B 809M 733M 678M 612M 1.15B 76.3B 1.19B 8.15B 3.23B 40.76B 3.04B 2.97B 129B
Net income -122M -111M -102M -92.27M -174M -11.5B -180M -1.23B -487M -6.14B -458M -448M -19.51B -79.32M -71.88M -66.49M -59.99M -113M -7.48B -117M -799M -317M -4B -298M -291M -12.68B
Net Debt -105M -95.59M -88.41M -79.77M -150M -9.95B -156M -1.06B -421M -5.31B -396M -387M -16.86B -210M -190M -176M -159M -299M -19.79B -310M -2.11B -838M -10.57B -788M -771M -33.56B
Projected Income Statement - Annual - NovoCure Limited
Logo NovoCure Limited
NovoCure Limited is a global oncology company with a proprietary platform technology called Tumor Treating Fields (TTFields), which are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. The Company's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Its Optune Gio is approved by the FDA under the Premarket Approval pathway for the treatment of adult patients with newly diagnosed glioblastoma together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. Its Optune Lua is approved by the FDA under the PMA pathway for the treatment of adult patients with metastatic non-small cell lung cancer concurrent with PD-1/PD-L1 inhibitors or docetaxel following progression on or after a platinum-based regimen.
Employees
1,605
Date Price Change Volume
13/11/26 USD 11.83 +0.94% 1,051,731
12/11/26 USD 11.72 -2.25% 1,246,673
11/11/26 USD 11.99 +1.52% 1,533,015
10/11/26 USD 11.81 -5.75% 1,929,014
09/11/26 USD 12.53 -5.65% 2,797,535
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
MarketScreener Ratings - NovoCure Limited
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
11.83USD
Average target price
26.14USD
Spread / Average Target
+120.99%
  1. Stock Market
  2. Stocks
  3. NVCR Stock